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We investigated the effect of glaucoma (GL) on nerve growth factor (NGF) presence in two brain visual
areas. Rats with elevated intraocular pressure (EIOP), induced by hypertonic saline injection in the epi-
scleral vein, were treated with eye topical application of saline or NGF. Rats were subsequently sacriﬁced,
and brain tissues were used for immunohistochemical, biochemical, and molecular analyses. We found
that GL alters the basal level of NGF and NGF receptors in brain visual centers and that NGF eye applica-
tion normalized these deﬁcits. These ﬁndings demonstrate that the reduced presence of NGF can arise
due to degenerative events in retinal and brain visual areas.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Glaucoma (GL) is an ocular disorder characterized by optic
nerve (ON) degeneration and loss of retinal ganglion cells (RGCs)
(Domenici, Berardi, Carmignoto, Vantini, & Maffei, 1991; Gupta &
Yucel, 2001; Morrison, Moore, Deppmeier, Gold, Meshul, & John-
son, 1997). Although elevated intraocular pressure (IOP) is the
main risk factor for GL, other mechanisms appear to be implicated
in this ocular disorder since GL can develop in the absence of ele-
vated IOP (Sommer, 1989). GL is characterized not only by RGC loss
but also by degeneration in the post-retinal pathways. It has been
observed that neural cells localized in the lateral geniculate nu-
cleus (LGN) and visual cortex (VC) display degenerative changes
in animal models of GL (Glovinsky, Quigley, & Dunkelberger,
1991; Gupta & Yucel, 2001; Gupta & Yucel, 2003; Yucel, Zhang,
Gupta, Kaufman, & Weinreb, 2000; Yucel, Zhang, Weinreb,
Kaufman, & Gupta, 2001). Moreover, electrophysiological studies
in humans indicate that both retinal cells and post-retinal struc-
tures are functionally impaired in GL (Parisi, 2001). Other studies
have shown that the reduced presence of biological mediators pro-
duced and released by these brain regions and/or by retinal cells
might be implicated in RGC death and loss of ON axons (Nucci,
Morrone, Rombola, Nistico, Piccirilli, & Cerulli, 2003; Yucel et al.,
2000; Yucel et al., 2001). This hypothesis is supported by ﬁndingsll rights reserved.showing that the administration of neurotrophic factors, such as
nerve growth factor (NGF), can differentially modulate the develop-
ment of the geniculate-cortical pathway (Kaushik, Pandav, & Ram,
2003; Riddle, Lo, & Katz, 1995) (Schoups, Elliott, Friedman, & Black,
1995) and promote regeneration of axons and damaged retinal gan-
glion cells (RGCs) (Pearson & Stofﬂer, 1992; Schoups et al., 1995;
Watanabe, Tokita, Kato, & Fukuda, 2003; Yip & So, 2000).
NGF is the ﬁrst discovered and best characterized member of
the growth factor family that includes brain derived neurotrophic
factor (BDNF) and neurotrophin-3/4 (Connor & Dragunow, 1998;
Sofroniew, Howe, & Mobley, 2001). The biological effects of NGF
are mediated by two NGF receptors: the high-afﬁnity receptor,
tyrosine kinase (TrkA), and the low-afﬁnity receptor, p75, located
on the surface of NGF-responsive cells (Aloe, Tirassa, & Bracci-
Laudiero, 2001; Casaccia-Bonneﬁl, Gu, & Chao, 1999; Sofroniew
et al., 2001). Impairment in the expression of these receptors
and/or their ligands can alter the functional activity of NGF-
responsive cells (e.g. retinal cells, Müller cells, photoreceptors,
and RGCs of developing and adult rodents) in the nervous system
(Connor & Dragunow, 1998; Sofroniew et al., 2001) and visual sys-
tem (Caminos, Becker, Martin-Zanca, & Vecino, 1999; Karlsson,
Clary, Lefcort, Reichardt, Karten, & Hallbook, 1998; Lambiase &
Aloe, 1996; Lenzi, Coassin, Lambiase, Bonini, Amendola, & Aloe,
2005). A possible functional role for NGF in cells of the visual sys-
tem is also suggested by ﬁndings that intraocular administration of
NGF reduces RGC degeneration following rat ON section
(Carmignoto, Maffei, Candeo, Canella, & Comelli, 1989), reduces
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Centofanti, Micera, Manni, Mattei, De Gregorio, de Feo, Bucci, &
Aloe, 1997), and prevents the shift in ocular dominance distribu-
tion of visual cortical neurons in monocular deprived rats (Dome-
nici, Parisi, & Maffei, 1992; Domenici et al., 1991; Maffei, Berardi,
Domenici, Parisi, & Pizzorusso, 1992; Pizzorusso, Porciatti, Tseng,
Aebischer, & Maffei, 1997). However, no investigation into the role
of NGF in this animal model of GL has been performed to date.
We have recently reported that conjunctival application of NGF
can reach brain cholinergic neurons and suggested that high
molecular weight protein can be safely delivered into the brain
via the ocular surface to promote the recovery of damaged brain
cells (Chen, Fawcett, Rahman, Ala, & Frey, 1998; Di Fausto, Fiore,
Tirassa, Lambiase, & Aloe, 2007; Koevary, 2003; Koevary, Lam,
Patsiopoulos, & Lake, 2003; Lambiase, Pagani, Di Fausto, Sposato,
Coassin, Bonini, 2007). This evidence raised questions about
whether eye-applied NGF can reach the brain’s visual regions
and whether NGF affects the deﬁcits induced by GL on cells of
the VC and LGN.
In the present study, we used this rat model of GL as an ap-
proach to investigate the effects of GL on cells of the LGN and VC
and for understanding the role of eye-applied NGF on possible neu-
rodegenerative events linked to NGF-responsive cells in these brain
visual regions.2. Materials and methods
2.1. Animals, surgical procedures, and treatment
GL was induced in right eye of adult male Sprague Dawley rats
(n = 135) following the procedure described previously (Morrison,
Johnson, Cepurna, & Jia, 2005; Morrison et al., 1997). Brieﬂy, deeply
anesthetized rats received 50 ll of hypertonic saline injected into
the right episcleral vein, causing elevated ocular hypertension by
sclerosis of the aqueous outﬂow pathways. Rats were housed in a
constant low-light environment (40–90 lux) to minimize IOP circa-
dian oscillation. A calibrated TonoPen XL tonometer (Mentor,
Norwell, MA) was used for daily monitoring of IOP under topical
anesthesia. Each daily IOP value was determined as the mean of
ten valid readings. Twelve rats (about 9%) of hypertonic saline in-
jected with an IOP less that 30 mmHg were classiﬁed as non-glau-
comatous rats and were not used for this study. The left eye was
used as a non-glaucomatous control.
Five rats died within 24 h after the induction of IOP elevation.
The remaining rats were divided two groups (n = 65 each), housed
in single cages in a constant low-light environment, and treated
daily with NGF or vehicle applied as collyrium (see also Ref. (Di
Fausto et al., 2007)). The ﬁrst group of rats (GL + V) received
20 ll of vehicle solution (V) consisting of 0.9% NaCl twice a day
in both eyes. The left non-glaucomatous eye is indicated as
(CNTL + V), and the right glaucomatous eye is indicated as
(IPSL + V). The second group of rats (GL + N) received 20 ll of puri-
ﬁed NGF (N) dissolved in V at a concentration of 200 lg/ml in both
eyes. In this group of rats, the left non-glaucomatous eye is indi-
cated as CNTL + N and the right glaucomatous eye as IPSL + N.
Thus, control (left) eyes (CNTL + V and CNTL + N) project to the
right LGN and VC, whereas glaucomatous (right) eyes (IPSL + V
and IPSL + N) project to the left LGN and VC. Two other groups of
20 healthy (not glaucomatous) adult rats received either: a) no
treatment at all (group C) or b) NGF in the right eye (NGF-C) and
vehicle in the left eye (V-C). These groups were used as additional
controls.
Ocular treatments began one day after the induction of GL and
continued for 35 consecutive days. To measure IOP, we used
TonoPen XL tonometer (Mentor, Norwell, MA) under topical anes-thesia. IOP values were evaluated weekly and determined as the
mean of ten valid readings as previously described (Morrison
et al., 2005). Animals were handled routinely prior to injection to
allow reproducible baseline IOP measurements. Intraocular pres-
sures following episcleral vein injections of hypertonic saline were
determined in awake animals using one drop of 0.5% proparacaine
hydrochloride instilled in each eye. Animals were gently restrained
with light hand pressure, and TonoPen measurements obtained
using the above criteria.
Mean intraocular pressure changes over the time of pressure
elevation were calculated for each eye, together with the standard
error of the mean. Rats were sacriﬁced 1, 2, 3, 4, and 5 weeks after
the induction of GL and/or NGF administration. We used ﬁve rats
per group for morphological analysis and eight rats per group for
biochemical analysis. Since no statistically signiﬁcant structural
or biochemical differences in NGF or NGF receptor expression
was found in the LGN and VC during the ﬁrst 4 weeks (data not
shown) and our previous studies indicated that the expression of
anti-apoptotic signals are markedly down-regulated and pro-apop-
totic signal up-regulated 5 weeks after the induction of GL (Coas-
sin, Lambiase, Sposato, Micera, Bonini, & Aloe, 2008), we will
present and discuss the results obtained with rats 5 weeks after
the induction of GL.
All experiments were performed in compliance with the intra-
mural Ethical Committee for the use of Animal care, National and
International laws (EEC council directive 86/609, OJ L 358, 1,
December 12, 1987), ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research.
2.2. Chemicals
The ELISA ‘‘NGF EmaxTM Immunoassay System number G7631”
was purchased by Promega (Madison, WI, USA); anti-p75 receptor
and anti-TrkA receptor were purchased from UPSTATE (Temecula,
CA, USA); and b-actin from Sigma (SIGMA, Saint Louis, MO, USA).
A monoclonal antibody against choline acetyl-transferase (anti-
ChAT) was generously provided by Dr. Costantino Cozzari, Institute
of Cellular Biology, CNR, Italy (Lambiase & Aloe, 1996; Lenzi et al.,
2005); Horseradish peroxidase-conjugated anti-rabbit IgG and
anti-mouse IgG were purchased from Cell Signaling Technology
(Danvers, MA, USA); and ECL chemiluminescent HRP substrate
from Millipore Corporation (Billerica, MA, USA).
The 2.5 S puriﬁed NGF obtained fromMicrolab Company, Roma,
Italy or was puriﬁed from adult male mouse submaxillary salivary
glands following the described method (Bocchini & Angeletti,
1969).
2.3. Tissue collection and extraction
Rats were deeply anesthetized with an overdose of Nembutal,
and cerebrospinal ﬂuid (CSF) and blood samples were collected
separately from each rat. Brain tissues (right and left LGN and
VC) were dissected out as previously reported (Amendola, Fiore,
& Aloe, 2003). The CSF was removed from brain 3rd ventricle with
glass micropipettes, blood collected after decapitation, and serum
separated from blood cells by centrifugation 5 min at 5.000 rpm.
For LGN and VC dissection, brains were placed on a cold glass dish
under a stereomicroscope. The right and left LGN and VC areas
were identiﬁed as previously reported (Amendola et al., 2003;
Palkovits & Brownstein, 1988), quickly removed, and then stored
at 70 C until used for biochemical analysis of NGF and NGFR
presence.
For NGF determination, brain tissues were homogenized with
ultrasonication in extraction buffer (20 mM Tris-acetate, pH 7.5,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium-pyro-
phosphate, 1 mM orthovanadate, 1 mM b-glycerolphosphate,
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4 C for 10 min at 13,000 rpm. The resultant supernatants were
recovered and used for NGF and NGF receptor determination.
2.4. Histological analysis of the retinal damage
Rats were sacriﬁced with an overdose of Nembutal, and eye
cups (n = 5 rats from each experimental group) were ﬁxed in Bouin
ﬂuid for 1 week. After several washes, sections of the eye were cut
at 20 lm and stained with hematoxylin and eosin.
To estimate the number of RGCs, we used sections (ten for each
eye) located approximately 350 mm distant from the ON head. The
mean numbers of retinal ganglion cells present in 0.25 mm2 were
counted under 200 magniﬁcations with the aid of a square grid.
The results were then averaged to generate data for one eye.
2.5. Ultra structural analysis
To assess the existence of ON ﬁber loss, the ONs of control
(n = 4) and glaucomatous (n = 4) eyes were ﬁxed in 4% glutaralde-
hyde in 0.1 phosphate buffer, pH 7.2 for 24 h, washed with fresh
buffer, and then post-ﬁxed in 1% OsO4 in the same buffer. ONs
were then dehydrated with ascending ethanol and acetone and
embedded in 812/Spurr’s low viscosity resin. Thin sections were
then cut with an ultramicrotome and collected on 200 mesh grids.
Sections were stained with uranyl acetate and lead citrate and
viewed under an electron microscope.
2.6. NGF assay
The tissue concentration of NGF was measured in the ON (n = 8)
of each experimental group by a highly sensitive and speciﬁc two-
site enzyme immunoassay ELISA kit ‘‘NGF EmaxTM Immunoassay
System number G7631” from Promega, (Madison, WI, USA) follow-
ing the instructions provided by the manufacturer. The amount of
rat NGF was determined from the regression line for the NGF stan-
dard (ranging from 7.8 to 500 pg/ml of puriﬁed mouse NGF), Incu-
bation conditions were similar for each assay, and all assays were
performed in duplicate.
2.7. Immunohistochemistry
Rats (n = 5 per experimental group) were anesthetized and
transcardially perfused with 4% paraformaldeyde in 0.1 M phos-
phate-buffered saline (PBS), pH 7.4; brain and eye cups removed
and post-ﬁxed overnight at room temperature with the same ﬁxa-
tive. Tissues were then left overnight in 0.1 M PBS containing 20%
sucrose, and coded 20 lm thick sections were then cut with a cryo-
stat (Leica CM 1850 UV, Germany) at 20 C and used for immuno-
histochemical analysis. Free-ﬂoating sections were exposed to 3%
hydrogen peroxide (H2O2) and 10% methanol (W/V) for 20 min,
blocked in 0.1 M PBS containing 10% horse serum for 1 h, and then
incubated overnight at 4 C with antibodies against TrkA, p75, or
ChAT. Sections were exposed to biotinylated anti-mouse IgG
(1:300, Vector Laboratories) with 2% horse serum for 2 h at room
temperature and then to an avidin-biotinylated horseradish perox-
idase complex (Vector Laboratories) in 0.1 M PBS with 0.1% Triton
X-100 for another 2 h at room temperature. This was followed by
treatment for 150 with a 0.1 M solution of 3,30-diaminobenzidine
(DAB) (Sigma Chemical Company) in 0.1 M PBS 0.1% Triton X-
100, to which 0.01% of H2O2, 0.025% cobalt chloride, and 0.02%
nickel ammonium sulfate were added as chromogens. All sections
studied passed through all procedures simultaneously to minimize
any differences due to immunohistochemical staining procedures.
Staining speciﬁcity was assessed by omission of primary
antibodies.To estimate the number of immunostained ChAT nerve cells, we
examined ipsilateral (IPSL) and controlateral (CNTL) coronal brain
sections (n = 7) containing the LGN, spanning from 3.80 mm to
5.20 mm relative to bregma (see brain atlas by (Paxinos,
1982)). ChAT-positive cells were counted in non-overlapping ﬁelds
using the Nikon-Lucia image processing and analysis program,
which automatically selects only cell bodies but not small frag-
ments or cells that do not have a complete soma.
2.8. Western blotting analysis
ONs (n = 6) from each experimental group were homogenized
in lysis buffer (0.01 M Tris–HCl buffer (pH 7.4) containing 0.1 M
NaCl, 1 mM EDTA, 1 mM EGTA, 2 mM PMSF, 50 lM leupeptin,
100 lg/ml pepstatin, and 100 lg/ml aprotinin) at 4 C. After
8000 g centrifugation for 20 min, the supernatants were used for
Western blotting. Samples (30 lg of total protein) were dissolved
with loading buffer (0.1 M Tris–HCl buffer (pH 6.8) containing
0.2 M DTT, 4% SDS, 20% glycerol, and 0.1% bromophenol blue), sep-
arated by 8% SDS-PAGE, and electrophoretically transferred to
PVDF membrane overnight. The membranes were incubated for
1 h at room temperature with blocking buffer (5% non-fat dry milk,
10 mM Tris, pH 7.5, 100 mM NaCl, and 0.1% Tween-20).
Membranes were washed three times for 10 min each at room
temperature in TTBS (10 mM Tris, pH 7.5, 100 mM NaCl, and 0.1%
Tween-20), followed by incubation at 4 C with primary antibodies
overnight. Membranes were washed three times for 10 min each at
room temperature in TTBS and incubated for 1 h with either horse-
radish peroxidase-conjugated anti-rabbit IgG or horseradish per-
oxidase-conjugated anti-mouse IgG as the secondary antibody.
The blots were developed with ECL chemiluminescent HRP sub-
strate (Millipore Corporation, Billerica, USA) as the chromophore.
A personal computer and the public domain (http://www.rsb.info.-
nih.gov/ij/) Image J software were used to evaluate band density,
which was expressed as arbitrary units of gray level. The ImageJ
software determines the optical density of the bands using a gray
scale thresholding operation. The optical density of b-actin bands
was used as a normalizing factor. For each gel/blot, the normalized
values were then expressed as a percentage of the relative normal-
ized controls and used for statistical evaluation.
2.9. Statistical analyses
Statistical evaluations were performed using the StatView pack-
age for Windows, and data were expressed as mean and S.E.M.
TrkA and p75 optical density data fromWestern blot analyses were
evaluated using an analysis of variance (one-way ANOVA) followed
by a Tukey-Kramer post-hoc test. A p-value less than 0.05 was con-
sidered to be statistically signiﬁcant.3. Results
We ﬁrst assessed whether the experimental approach we used
induced elevated IOP and loss of cells in the retinal ganglion layer.
Time-course analysis revealed progressive elevation of IOP
(Fig. 1A). One week after hypertonic saline injection, the IOP of
the glaucomatous eye (IPSL + V) reached the highest value
(42.7 ± 3.7 mmHg). It then decreased during the second week
post-treatment to 35.7 ± 2.5 mmHg, compared to the IOP of the un-
treated eyes (CNTL + V) of 26.9 ± 2.6 mmHg (mean ± SEM). NGF
administration has no statistically signiﬁcant effect on the EIOP
of glaucomatous eye.
Histological analysis of retinas revealed that elevated IOP caused
loss of cells in the RGL (Fig. 1B and C). In glaucomatous rats, a reduc-




















































Fig. 1. The intraocular pressure of adult rats under normal conditions and during the progression of the experimentally-induced glaucoma (A). IOP increased constantly
during the ﬁrst week post-GL, decreased moderately during the second week, and then remained signiﬁcantly (p < 0.05) higher than that of not glaucomatous eyes treated
with vehicle or NGF. Group IPSL + V = glaucomatous right eye treated with vehicle; CTNL + V = left controlateral eye treated with vehicle. Histological preparation of a retina
stained with hematoxylin-eosin showing the reduced presence of retinal ganglion cells of control (B) and glaucomatous (C) retinas. Retinal ganglion layer (RGL), Inner retinal
layer (INL); Outer retina layer (ONL). Bars: 150 lm. Time-course analysis and the progressive loss (arrow) of retinal ganglion cells in glaucomatous eye, in 0.5 lm/length,
compared to control (D). The difference reached statistical signiﬁcance (p < 0.05) during the second week after GL induction. Representative section at the ultrastructural level
of the ON of glaucomatous (F) and control (E) retinas showing axon swelling and myelin debris. Bars: 0.4 lm.
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dily (p < 0.05) and 5weeks later the RGC reduction in glaucomatous
eyewas about 50% compared to control eye (Fig. 1D). Ultrastructural
analysis revealed that elevated IOP caused axon swelling andmyelin
debris in the ON after 5 weeks (Fig. 1E and F).
3.1. Effect of GL and topical NGF on serum and CSF levels of NGF
As reported in Fig. 2A, GL (GL + V) induces no changes in serum
NGF protein levels but lowers NGF content in the CSF (Fig. 2B) in
comparison to control rats. This ﬁnding suggests that the NGF pres-
ent in the CSF is taken up by damaged retinal or brain neurons.Moreover, topical eye NGF application in glaucomatous rats
(GL + N) had no effect on IOP or concentrations of NGF in the serum
but enhanced NGF presence in the CSF (GL + N versus GL + V:
p < 0.05). This latter increase is most likely due to the accumulation
of administered NGF.
3.2. Effect of NGF and NGFR in the LGN of glaucomatous rats
The topographic region of the LGN of rats removed for measur-
ing the concentration of NGF is illustrated in Fig. 3A (dark area). As
shown in Fig. 3B, GL caused a statistically signiﬁcant reduction in
the concentration of NGF in the LGN (IPSL + V versus CNTL + V;


































Fig. 2. Concentration of NGF in the serum (A) and CSF (B) of glaucomatous rats
treated and untreated with topical NGF eye drops. Note that glaucoma caused a
decrease of NGF contents in the CSF but not serum (C versus GL + V: p < 0.05). This
decrease is most likely due to a major requirement for NGF in degenerating retinal
or brain NGF-responsive cells. Alternatively, it may be due to reduced synthesis and
release by local NGF-producing cells. Topical application of NGF increased the NGF
levels in the CSF (GL + V versus GL + N: p < 0.05) but had no effect on these levels in
the serum.
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restored the presence of NGF to nearly normal levels (IPSL + N ver-
sus IPSL + V; p 6 0.01). This ﬁgure also indicates that NGF adminis-
tration has no statistically relevant effect (p > 0.05) on normal eyes
(CNTL + N versus CNTL + V).
We next investigated whether NGF receptive cells are present in
the LGN. Immunohistochemical studies carried out on serial brain
sections showed that both high-afﬁnity (TrkA, Fig. 3C) and low-
afﬁnity (p75, Fig. 3D) NGF receptors are expressed by cells of the
LGN. TrkA is markedly expressed by nerve ﬁbers, whereas p75 is
found mainly in nerve cell bodies. As reported in Fig. 3E–H, Wes-
tern blot analyses revealed that GL enhanced the presence of TrkA
protein in the LGN (Fig. 3E, G IPSL + V versus CNTL + V; *p < 0.05)
and that eye NGF application enhanced this expression (Fig. 3E,
G IPSL + N versus IPSL + V; **p 6 0.01). On the contrary, GL had
no effect on the expression of p75 in the LGN (Fig. 3F, H IPSL + V
versus CNTL + V), and eye NGF application enhanced p75 protein
expression (Fig. 3F, H IPSL + N versus IPSL + V; p < 0.05). NGF
administration had no effect on the LGN of normal rats (CNTL + N
versus CNTL + V, p > 0.05).
3.3. NGF and NGFR in the VC of glaucomatous rats
The topographic region of the VC of rats removed for measuring
the concentration of NGF is illustrated in Fig. 4A (dark area). Up to
the forth week after GL induction, no statistically signiﬁcant differ-
ences were observed (data not shown). Fig. 4B shows that GL sig-
niﬁcantly reduced the concentration of NGF in the VC, (IPSL + Vversus CNTL + V, p 6 0.01), and topical NGF application for 35 con-
secutive days normalized the NGF concentration (Fig. 4B, IPSL + N
versus IPSL + V; p 6 0.01). Immunohistochemical analysis of VC
sections indicated that both TrkA (Fig. 4C) and p75 (Fig. 4D) recep-
tors were expressed by cells of the VC, suggesting that NGF was
produced by and acted upon cells of the VC. As demonstrated in
Fig. 4E–H, Western blot analyses indicated that GL down-regulated
the expression of TrkA in the VC (Fig. 4E, G IPSL + V versus
CNTL + V) and that eye NGF application was unable to normalize
this decrease (Fig. 4E, G IPSL + N versus IPSL + V). Moreover, GL sig-
niﬁcantly reduced the expression of p75 in the VC (Fig. 4F and H,
IPSL + V versus CNTL + V; (*p < 0.05)), and eye NGF application fur-
ther reduced the expression of p75 protein (Fig. 4F and H, IPSL + N
versus CNTL + V; **p 6 0.01).
3.4. Effect of eye NGF application in naive rats
The above observations raised questions about the effect of eye
NGF application in the LGN and VC of healthy (non-operated) rats.
As shown in Fig. 5, the concentration of NGF in the LGN and VC of
control (C), vehicle (C-V), and NGF-treated (NGF-C) rats after 35
days was nearly the same. This observation suggests that NGF ex-
erts its effect in injured or degenerating, but not intact tissues. No
statistically signiﬁcant differences were found upon comparison to
the levels in controls (Figs. 3 and 4).
3.5. GL reduces the number of ChAT-immunopositive ﬁbers in the LGN
As NGF plays a crucial role in preventing degeneration of brain
cholinergic neurons (Connor & Dragunow, 1998; Sofroniew et al.,
2001) and brain cholinergic projections exert an important modu-
lator of visual activity in the LGN and VC (Carden, Datskovskaia,
Guido, Godwin, & Bickford, 2000), we examined the distribution
of ChAT immuno-labeled cells in the IPSL and CNTL LGN and VC
of glaucomatous rats that had been treated or untreated with
NGF for 35 days. Fig. 6A–C show that GL markedly reduced the
number of ChAT-positive cells in the LGN receiving input from
the glaucomatous eye (B) in comparison to the LGN corresponding
to the healthy eye (A); NGF application prevented the loss of ChAT-
positive neurons (C). Quantitative analysis in Fig. 6D indicated that
experimental GL markedly reduced the number of ChAT-positive
cells in the LGN (IPSL + V versus CNTL + V; p 6 0.01). This study re-
vealed that eye NGF administrations normalized these deﬁcits
(IPSL + N versus IPSL + V; p 6 0.01) (Fig. 6D). No difference in the
number of ChAT-immuno-positive cells was found in the VC of
glaucomatous rats compared to controls (data not shown).4. Discussion
In this study, we investigated whether (i) experimentally-in-
duced GL in adult rats alters the presence of NGF and its receptors
in the LGN and VC and (ii) eye topical NGF application can prevent
these deﬁcits. We found that GL reduces the concentration of NGF
in the CSF, LGN, and VC and causes no signiﬁcant changes in serum
NGF levels. Moreover, immunohistochemical and biochemical
analyses revealed that GL enhances the presence of the TrkA recep-
tor in the LGN and decreases the expression of this receptor in the
VC, whereas the presence of the p75 receptor is unaffected in the
LGN and down-regulated in the VC. Topical eye NGF application
for 35 consecutive days enhances the concentration of NGF in the
CSF of glaucomatous rats and normalizes its presence in the VC
and LGN. NGF application induced up-regulation of TrkA in the
LGN but not VC, and it enhanced the expression of p75 in the
LGN and reduced its presence in the VC. A summary of all results
is given in Table 1.













































































Fig. 3. (A) Schematic representation of rat brain sections indicating the LGN area used for biochemical analysis. (B) The concentration of NGF in the LGN of control and
glaucomatous rats treated and untreated with NGF. Note the signiﬁcant (p < 0.01) decrease of NGF presence in the LGN of glaucomatous rats (group IPSL + V) compared to
controls (group CNTL + V) and nearly complete normalization after daily NGF treatment (group IPSL + N). No signiﬁcant changes in NGF levels were found in non-
glaucomatous rats after NGF administration (CNTL + N versus CNTL + V: p > 0.05). TrkA (C) or p75 (D) immunopositivity in the LGN of normal rats. Note that TrkA is mainly
localized to nerve ﬁbers (arrows), whereas p75 is in cell bodies (arrows). Bars: 80 lm. Western blot analysis of TrkA (E and G) and p75 (F and H) proteins in the LGN. GL
caused up-regulation of TrkA in the LGN (IPSL + V versus CNTL + V), and eye NGF application further enhanced this increase (IPSL + N versus IPSL + V). In control rats, eye NGF
administration augmented TrkA expression (CNTL + N versus CNTL + V). GL induced no changes (F, H) in p75 protein expression (IPSL + V versus CNTL + V), whereas eye NGF
application up-regulated p75 expression in comparison to glaucomatous (IPSL + N versus IPSL + V) and control (IPSL + N versus CNTL + V) eyes. No signiﬁcant NGF effect was
found in control eyes (CNTL + N versus CNTL + V: p > 0.05).
V. Sposato et al. / Vision Research 49 (2009) 54–63 59The functional signiﬁcance and mechanism(s) causing the dif-
ferent expression of low and high-afﬁnity NGF receptors in glauco-
matous VC and LGN are not known. Most probably, they are relatedto the effects induced by GL on apoptotic cell death and the
different role played by NGF receptors in cell death and survival
(Casaccia-Bonneﬁl et al., 1999; Middleton & Davies, 2001;







































































Fig. 4. Schematic representation of rat brain sections (A) indicating the VC area removed for biochemical analysis. Fig. B shows a signiﬁcant (p < 0.01) decrease of NGF protein
in the VC of glaucomatous rats (IPSL + V versus CNTL + V) and its normalization after eye administration of NGF (IPSL + N versus IPSL + V). Immunopositivity for TrkA (C) and
p75 (D) in cells of the VC of normal rats. Both TrkA and p75 were predominantly expressed in cell bodies (arrows). Bars: 80 lm. GL down-regulates, though not markedly
(IPSL + V versus CNTL + V), the TrkA band in the VC samples upon Western blotting (E, G). Eye NGF administration was unable to normalize this deﬁcit (IPSL + N versus
IPSL + V). GL signiﬁcantly down-regulated the expression of p75 (F, H) (IPSL + V versus CNTL + V), and NGF administration further reduced the expression of p75 (IPSL + N
versus CNTL + V).
60 V. Sposato et al. / Vision Research 49 (2009) 54–63Sofroniew et al., 2001). This hypothesis is in line with the observa-
tion that a major mechanism of neuron loss during GL is related to
an increase in RGC susceptibility to apoptotic mechanisms (Nucci
et al., 2003), because NGF/NGF receptors play a marked role in thisprocess (Ambati, Canakis, Miller, Gragoudas, Edwards, Weissgold,
Kim, Delori, & Adamis, 2000).
One question raised by our observations is how eye NGF appli-



















Fig. 5. NGF levels in extracts from the LGN and VC of naive control rats (C) and
healthy rats treated with eye drops of vehicle (V-C) or NGF (NGF-C) for 35
consecutive days. No statistically signiﬁcant differences (p > 0.05) in NGF concen-
tration were found in brain visual areas in Vehicle (V-C) or NGF-treated (NGF-C)
rats, suggesting that NGF does not accumulate in the brain after topical eye
application.
V. Sposato et al. / Vision Research 49 (2009) 54–63 61strated for insulin and other molecules, the mechanism through
which NGF ocular application reaches the brain neurons the
existence of the anatomical connections between the eye and the
brain or via nasal mucosa, naso-lacrimal duct, brain ventricles, or


























Fig. 6. The effect of GL and eye vehicle or NGF treatment on ChAT immuno-labeled cells
immunohistochemically stained for ChAT in the CNTL + V (A), IPSL + V (B), and IPSL + N
group was compared to the CNTL + N group (p > 0.05). Bars: 80 lm Quantitative determi
positive cells in the IPSL + V LGN compared to the CNTL + V LGN (p < 0.01). Eye NGF admKoevary et al., 2003; Lambiase et al., 2007; Schoenwald, Deshpande,
Rethwisch, & Barfknecht, 1997). This observation is in line with our
recent study (Lambiase et al., 2007) showing that NGF applied to
the ocular surface may reach some brain regions, such as the nu-
cleus basalis and septum, and promote the recovery of damaged
brain cells (Di Fausto et al., 2007). NGF and other members of
the neurotrophin family are known to play a marked role not only
in peripheral nerve cells, but also in brain cells via retrograde and
anterograde mechanisms. Moreover, axonal anterograde transport
of neurotrophins, including NGF, appears to be a widespread
mechanism (Altar & DiStefano, 1998; Conner, Lauterborn, & Gall,
1998; Cui, Tang, Hu, So, & Yip, 2002; Sofroniew et al., 2001; Wahle,
Di Cristo, Schwerdtfeger, Engelhardt, Berardi, & Maffei, 2003).
These suggest that deﬁcits in this mechanism could compromise
the structural and neurochemical plasticity of brain visual neurons.
Our observation that the presence of NGF and NGFRs in cells of the
LGN and VC is signiﬁcantly impaired in experimentally-induced GL
suggests that these NGF signaling are functionally involved in neu-
rodegenerative events occurring in retinal and visual brain regions
(Morrison et al., 2005; Parisi, 2001; Vickers, Hof, Schumer, Wang,
Podos, & Morrison, 1997).
An other question raised by our ﬁndings is the functional signif-
icance of NGF in the LGN and VC. Neurotrophins, and in particular





in the lateral LGN of glaucomatous rats. Representative sections of the lateral LGN
(C) groups. No differences of ChAT immunostaining were found when the CNTL + V
nation showed that experimental glaucoma markedly reduced the number of ChAT-
inistration normalized this decline (IPSL + N, versus IPSL + V; p < 0.01), D.
Table 1
Summary of results.
CSF Serum LGN VC
NGF TrkA p75 NGF TrkA p75 NGF TrkA p75 NGF TrkA p75
GL/normal IOP ; – – 0 – – ;; " 0 ;; ; ;
GL + NGF/GL "" – – 0 – – "" "" " "" 0 ;;
0: no change; –: not done.
62 V. Sposato et al. / Vision Research 49 (2009) 54–63plasticity of both LGN and VC neurons (Pizzorusso et al., 1997;
Schoenwald et al., 1997). Present data showing that NGF adminis-
tration in glaucomatous rats enhances the presence of ChAT-posi-
tive neurons in the LGN suggest that NGF may also modulate the
synthesis and/or release of biological mediators in cholinergic neu-
rons localized not only in the forebrain (Connor & Dragunow,
1998) but also in the LGN (Carden et al., 2000).
The possibility of a role for NGF in cells of the visual system is
suggested by a number of other recent ﬁndings. For example, intra-
ocular administration of NGF reduces RGC degeneration following
rat ON section (Carmignoto et al., 1989) and rabbit ocular hyper-
tension (Lambiase et al., 1997), and it prevents the shift in ocular
dominance distribution of visual cortical neurons after monocular
deprivation in rats (Domenici et al., 1991; Domenici et al., 1992;
Maffei et al., 1992; Pizzorusso et al., 1997) and in rats with inher-
ited retinopathy (Lambiase & Aloe, 1996; Lenzi et al., 2005). The ef-
fects of NGF eye drops, a simple non-invasive treatment, in
normalizing NGF and modulating p75 and TrkA expression during
GL encourage further studies to investigate the potential therapeu-
tic use of NGF in degenerative diseases of the visual pathway. Alto-
gether, our ﬁndings are in line with the hypothesis that
neurotrophin function extends from retrograde, target-derived tro-
phic factors to anterograde, afferent and local, paracrine actions in
the VC, LGN, and retina (Rossi, Sala, & Maffei, 2002). It remains to
be established, however, whether prolonged NGF application could
provide a functional beneﬁt for the RGC, LGN, and VC damage in-
duced by GL.
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